

1 **Performance of microbiological tests for tuberculosis diagnostic according to the type**
2 **of respiratory specimen: a 10-year retrospective study**

3

4 Short title:

5 **Diagnostic tests for pulmonary tuberculosis**

6

7 **Authors**

8 Marc-Olivier Boldi¹, Justin Denis-Lessard¹, Rina Neziri¹, René Brouillet², Christophe von-
9 Garnier³, Valérie Chavez¹, Jesica Mazza-Stalder³, Katia Jaton², Gilbert Greub^{2,4}, Onya Opota²

10

11

12 **Affiliations**

13 (1) Faculty of Business and Economics, University of Lausanne, Switzerland.

14 (2) Institute of Microbiology, Lausanne University and University Hospital of Lausanne,
15 Lausanne, Switzerland.

16 (3) Pulmonary Division, Lausanne University Hospital, University of Lausanne, Lausanne,
17 Switzerland.

18 (4) Infectious Diseases Service, Lausanne University and University Hospital of Lausanne,
19 Lausanne, Switzerland.

20

21 Corresponding author: Onya Opota, onya.opota@chuv.ch

22

23 Key words:

24 Tuberculosis, microscopy, PCR, mycobacterial culture, bronchoalveolar lavage, bronchial
25 aspirate, sputum, induced-sputum, acid-fast bacilli (AFB).

26

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

27 **Abstract**

28 **Background:**

29 The microbial diagnosis of tuberculosis (TB) remains challenging and relies on multiple
30 microbiological tests performed on different clinical specimens. Polymerase chain reactions
31 (PCRs), introduced in the last decades has had a significant impact on the diagnosis of TB.
32 However, questions remain about the use of PCRs in combination with conventional tests for
33 TB, namely microscopy and culture. We aimed to determine the performance of microscopy,
34 culture and PCR for the diagnosis of pulmonary tuberculosis according to the type of clinical
35 specimen in order to improve the diagnostic yield and to avoid unnecessary, time and labor-
36 intensive tests.

37 **Methods:**

38 We conducted a retrospective study (2008-2018) on analysis (34'429 specimens, 14'358
39 patients) performed in our diagnostic laboratory located in the Lausanne University Hospital to
40 compare the performance of microbiological tests on sputum, induced sputum, bronchial
41 aspirate and bronchoalveolar lavage (BAL). We analysed the performance using a classical
42 "per specimen" approach and a "per patient" approach for paired specimens collected from the
43 same patient.

44 **Results:**

45 The overall sensitivities of microscopy, PCR and culture were 0.523 (0.489, 0.557), 0.798
46 (0.755, 0.836) and 0.988 (0.978, 0.994) and the specificity were 0.994 (0.993, 0.995), 1 (0.999,
47 1) and 1 (1, 1). Microscopy displayed no significant differences in sensitivity according to the
48 type of sample. The sensitivities of PCR for sputum, induced sputum, bronchial aspirate and
49 BAL were, 0.821 (0.762, 0.871), 0.643 (0.480, 0.784), 0.837 (0.748, 0.904) and 0.759 (0.624,
50 0.865) respectively and the sensitivity of culture were, 0.993 (0.981, 0.998), 0.980 (0.931,
51 0.998), 0.965 (0.919, 0.988), and 1 (0.961, 1) respectively. Pairwise comparison of specimens
52 collected from the same patient reported a significantly higher sensitivity of PCR on bronchial
53 aspirate over BAL ($p < 0.001$) and sputum ($p < 0.05$) and a significantly higher sensitivity of
54 culture on bronchial aspirate over BAL ($p < 0.0001$).

55 **Conclusions:**

56 PCR displayed a higher sensitivity and specificity than microscopy for all respiratory specimens,
57 a rational for a smear-independent PCR-based approach to initiate tuberculosis microbial
58 diagnostic. The diagnosis yield of bronchial aspirate was higher than BAL. Therefore, PCR
59 should be systematically performed also on bronchial aspirates when available.

60 **1. Introduction**

61 With over ten million new cases in 2020 and about 1,5 million deaths, tuberculosis represents
62 a major public health concern [1]. Rapid and reliable diagnosis is important to reduce morbidity
63 and mortality associated with tuberculosis and to control transmission. When tuberculosis is
64 suspected based on clinical symptoms, epidemiological information and radiological findings,
65 microbial confirmation is key to establish the diagnosis. Despite progress during the last
66 decades, the microbiological diagnosis of tuberculosis continues to be a challenge particularly
67 in paucibacillary disease. Historically, the diagnosis of tuberculosis was based on microscopy

68 and culture. Mycobacterial culture represents the reference method due to a low limit of
69 detection (< 10 organisms for liquid cultures) and because it gives access to the strain for
70 phenotypic antibiotic susceptibility test [1,2]. However, culture is challenging due to the slow
71 growth of *M. tuberculosis* and because it requires biosafety level three (BSL3) laboratories [3,4].
72 Microscopy based on the visualization of acid-fast bacilli provides rapid results (<30 minutes)
73 but has a limited sensitivity and specificity (limit of detection between 10^3 and 10^4 bacilli per ml)
74 [5]. In order to increase their sensitivity, these tests may need to be repeated over several
75 clinical specimen [1,6,7].

76 More recently, molecular diagnosis, in particular polymerase chain reaction (PCR) have
77 improved the diagnosis of tuberculosis with a limit of detection between 10 and 10^3 colony
78 forming units per ml and a turnaround time between two to six hours [2,6,8,9]. PCR was initially
79 available in laboratories specialized in molecular diagnostics, through methods developed in-
80 house assays [10,11]. Commercial all-inclusive systems, such as the GeneXpert system, now
81 allow a greater number of laboratories to perform this analysis independently of a specialized
82 infrastructure [6,8,9,12]. The GeneXpert system not only improved the initial diagnostic of
83 tuberculosis but can be used to assess patient's infectious potential, on the basis of the semi-
84 quantitative results [2,5,8]. In addition, rapid molecular test also shortens airborne isolation for
85 hospitalized patients with presumptive tuberculosis [13]

86 More than 70% of the tuberculosis infections are pulmonary tuberculosis, for which
87 sputum is the usual specimen collected in adults and older children who are able to collaborate.
88 Other respiratory specimens can be considered when patients are not able to provide sputum
89 or to increase microbial diagnostic yield [10]. This includes induced sputum, obtained by
90 nebulization of sterile hypertonic saline (3% or 7% saline solution inhaled) followed by coughing and
91 expectoration of airway secretions, bronchial aspirate, and bronchoalveolar lavages [14,15].

92 In this study, we aimed to assess the performance of the different tests for the microbial
93 diagnostic of tuberculosis according to the type of clinical specimen. Providing robust updated
94 data may enable to choose optimal combination of test and specimen to: i) reach the maximum
95 sensitivity, specificity and negative and predicative value, ii) prioritize the tests and specimens
96 in the situation of limited resources or shortage of material and iii) reduce unnecessary costs.

97 There is no standard method to address the performance of diagnostic tests, particularly
98 for tuberculosis where several microbiological tests on multiple clinical samples are frequently
99 required. We applied data analytics methods that integrate multiple parameters, including, the
100 type of microbiological test, the type of specimens, the sampling period, and the patients. In
101 this study, we performed both a classical "per specimen" method to determine the performance
102 of each diagnostic test and a "per patient" approach comparing paired specimens collected
103 from the same patient.

104 This study provides data to establish diagnostic stewardship guidelines and diagnostic
105 protocols. These data will help to establish more effective strategies to diagnose pulmonary
106 tuberculosis in order to increase the rate of documentation, to accelerate the diagnosis and
107 avoid unnecessary testing. In addition, it should provide analytical strategies that may also be
108 suitable to study other infectious diseases while keeping associated medical, social and
109 economic costs to a strict minimum.

110

111 2. Material and Methods

112 2.1 Study Design and data

113 Our laboratory is located in the Lausanne University Hospital (CHUV), a 1'500 beds tertiary-
114 care hospital in a low-tuberculosis-prevalence country (Switzerland), with approximately six
115 new cases per year per 100,000 population (Federal Office of Public Health;
116 <http://www.bag.admin.ch/>). The data included microbiology analyses for patients with
117 suspected mycobacterial infection from 2008 to 2018. They were automatically extracted from
118 the Laboratory Information System (MOLIS, CGM).

119 For all specimens, information regarding the microbial diagnostic of mycobacteria were
120 extracted. This included information regarding microscopy, PCR, cultures, molecular and
121 phenotypic resistance genes together with the type of specimen and the date of collection. Each
122 specimen was given a unique coded number. Similarly, each patient was given a unique coded
123 number. The database was generated to allow analysis by date of sampling and by patients
124 (see Section 2.4). For the microbial diagnostic of the disease, we generated a composite gold
125 standard including microbiological findings and epidemiological and clinical data (see Section
126 2.3). The final database included 34'429 specimens corresponding to 14'358 patients, including
127 8'587 sputum, 2'257 induced sputum, 8'610 bronchial aspirate and 4'576 BAL.

128

129 2.2 Clinical specimens and mycobacterial diagnostic test

130 This study focuses on three microbial diagnostic tests commonly used for the diagnostic of
131 mycobacterial infections, namely (i) microscopy (also named smear microscopy) for the direct
132 detection of acid-fast bacilli (AFB) in clinical specimen, (ii) PCR for the detection of DNA of *M.*
133 *tuberculosis* complex directly from clinical specimen and (iii) mycobacterial culture. Microscopy
134 consists in acid-fast bacillus staining achieved through a fluorescent auramine-thiazine red
135 staining on a heat-fixed smear as described in [8]. PCR consisted of either an in-house TaqMan
136 PCR targeting the multicopy *M. tuberculosis* IS6110 sequence, named PCR "MYTU" [11] or
137 using the all-inclusive rapid molecular test Xpert MTB/RIF and Xpert MTB/RIF Ultra (hereafter
138 named Xpert) (Cepheid, Ca, USA) [6,8,16]. Mycobacterial culture was achieved using
139 mycobacterial growth indicator tube (MGIT) that consists in culture tubes containing tris 4, 7-
140 diphenyl-1, 10-phenanthroline ruthenium chloride pentahydrate, an oxygen-quenched
141 fluorochrome embedded in silicone at their bottom. Utilization of free oxygen for growing
142 bacteria alleviates the fluorochrome quenching, resulting in fluorescence within the tube that
143 can be visualized under UV light, as explained in a previous publication [8].

144 All the microbial analyses were performed on the same sample after splitting it for AFB staining,
145 Xpert analysis and mycobacterial culture [8]. Sputum, induced sputum, bronchial aspirate and
146 bronchoalveolar lavage were processed as previously described [8]. In particular, samples with
147 a volume exceeding 3 mL were concentrated by centrifugation (30 minutes, 3000 g). In addition,
148 to increase the homogeneity of the sample before smear preparation, purulent sputum or
149 bronchial aspirates were solubilized with the mucolytic agent N-acetyl-L-cysteine (2% v/v pH
150 6.8) [8].

151

152 **2.3 Composite gold standard**

153 Mycobacterial culture is the gold standard for the diagnosis of *M. tuberculosis* because of its
154 lowest limit of detection (LOD < 10 organisms). However, it can be impaired by situation that
155 affect mycobacterial growth such as the introduction of an antibiotic treatment before sampling
156 [2]. We therefore used a composite gold standard based on microbiological results and clinical
157 data. Discrepant results in the diagnostic of active tuberculosis, especially specimen with
158 positive MTBC PCR and negative culture for *M. tuberculosis* complex, were manually cured
159 based on clinical and epidemiological data found in medical records. Specimens for which the
160 culture was contaminated by bacteria of the flora were excluded. Specimens with culture
161 positive with nontuberculous mycobacteria qualified as “MOTT” (Mycobacteria other than
162 tuberculosis) were considered negative for *M. tuberculosis*. This resulted in the “Gold Standard”
163 (GS) reference.

164

165 **2.4 Performance of the test depending on the clinical specimens**

166 We used two different approaches to determine the performance of microbiological tests
167 depending on the clinical specimens. We first used a common “per specimen” approach to
168 determine the global performance of microscopy, PCR, and culture according to the four types
169 of specimens and independently of the patient using the GS as reference. Then, in order to
170 provide more robust data we performed a “per patient” approach. It consists in pairwise
171 comparison for specimens collected the same day or during a window of 72 hours for the same
172 patient; indeed, samples from the same patient might not be collected the same day. For each
173 patient, the first sample was paired to the following sample if it was of a different type and within
174 a 72-hour window. All the combinations of the four types of specimens were analyzed using
175 this pairwise approach i) to measure the dependence between each pair of types of specimens
176 and ii) to calculate the performance of one sample type to predict a positive of any of the two
177 sample types.

178

179 **2.5 Statistics**

180 The performance measures consist in accuracy, sensitivity, specificity, positive and negative
181 predictive values. They were computed using GS as reference. Their respective 95%
182 confidence intervals were computed using the Clopper–Pearson method. The comparisons of
183 proportions were assessed with a two-sided proportion test with Yates’ continuity correction.
184 The dependence between pairs of types of specimens for the “per patient” approach is
185 measured by the Cohen’s Kappa.

186

187 **2.6 Ethics committee approval**

188 This study was approved by the relevant ethics committee, the *Commission Cantonale*
189 *d’Éthique de la Recherche sur l’Être Humain (CER-2020-00136)*.

190

191 **3. Results**

192 **3.1 Global performance of microscopy, PCR and culture for the** 193 **diagnostic of pulmonary tuberculosis.**

194 We first determined the global performance of microscopy. The sensitivity, 0.523 (0.489 –
195 0.557) and the PPV, 0.767 (0.730, 0.800) of microscopy were limited. The specificity, 0.994
196 (0.993, 0.995), and the NPV 0.982 (0.981, 0.984) were high but must be interpreted according
197 to the low prevalence of microscopy positive specimen 0.036 (0.034, 0.038) (Table 1 and Table
198 S1).

199 Regarding PCR, we first estimated the individual performance of the in-house TaqMan PCR
200 and the rapid molecular test Xpert. The sensitivity of the in-house TaqMan PCR, 0.799 (0.743,
201 0.848) and Xpert 0.812 (0.760, 0.858) were not significantly different (Table S2 and Table S3).
202 The specificity for both the in-house TaqMan PCR >0.999 (0.999, 1) and Xpert 0.999 (0.997,
203 1) were both very high. The NPV were also high but probably increased by the low prevalence
204 of PCR positive specimen (Table S7). Because the two PCR tests displayed similar
205 performance, we considered them as equal for the rest of the study and grouped them as
206 “PCR”. The global performance of PCR were: sensitivity 0.798 (0.755, 0.836), specificity 1
207 (0.999, 1), PPV 0.997 (0.983, 1) and NPV 0.988 (0.985, 0.990) (Table 2 and S2).

208 The culture displayed the highest performance for the diagnostic of tuberculosis using the GS
209 reference with a sensitivity of 0.988 (0.978, 0.994) and a specificity of 1 (1, 1) (Table 3 and
210 Table S3). In summary when considering all the clinical specimen, microscopy displays limited
211 sensitivity, PCR displays a higher sensitivity than microscopy and an excellent specificity and
212 culture displayed the highest sensitivity and specificity.
213

214 **3.3 Performance of microbiological tests according to the type of** 215 **specimen using a “per sample” approach or using “per patient”** 216 **pairwise comparisons.**

217 We next measured the dependence between the specimens using the “per patient” approach
218 and the Cohen’s kappa. Though the Cohen’s kappa is itself difficult to interpret and the
219 confidence intervals shown in the table were not corrected for multiple comparisons, a large
220 value of kappa means that the two sample bring the same information to some extent and thus
221 provides little “complementary” information and are so-called “supplementary”, i.e not really
222 needed. Conversely, a kappa close to zero means that the two sample are “complementary”.
223 The results are shown in Table S8, S9, S10 and S11. The data suggested that for each
224 technique, microscopy, PCR, and culture, most samples are supplementary (i.e. not all
225 needed), except i) for microscopy, induced sputum versus bronchial aspirate and BAL, ii) for
226 PCR, sputum versus induced sputum and iii) for the culture, induced sputum versus BAL.
227 Because of their low robustness, we do not want to over interpret these results by concluding
228 that the so-called “supplementary” tests don’t need to be performed, but this question has to
229 be tackled in additional work since it is however to our knowledge the first study showing such
230 high dependence & redundancy of the various tests.

231

232 **3.4 Performance of microscopy according to the type of respiratory** 233 **specimen.**

234 Using the classical “per specimen” approach—the sensitivities of microscopy for all specimen,
235 sputum, induced sputum, bronchial aspirate and BAL were 0.523 (0.489, 0.557), 0.605 (0.562,
236 0.647), 0.362 (0.265, 0.467), 0.362 (0.283, 0.447) and 0.462 (0.356, 0.569) respectively. The
237 sensitivity of sputum was higher than induced sputum (p-value < 0.0001) and bronchial aspirate
238 (p-value < 0.0001) (Table 4 and S4). However, using the “per patient” comparison approach,
239 for paired specimens collected within a window of 72h for the same patient, no significant
240 difference was observed for the various specimens (Table 4, S4 and S9). Altogether, these data
241 suggested a limited benefit of microscopy for tuberculosis microbial diagnosis in a low
242 prevalence setting.

243

244

245 **3.5 Performance of PCR according to the type of respiratory** 246 **specimen.**

247 Using the classical “per specimen” approach—the sensitivities of PCR for all specimen, sputum,
248 induced sputum, bronchial aspirate and BAL were 0.798 (0.755, 0.836), 0.821 (0.762, 0.871),
249 0.643 (0.480, 0.784), 0.837 (0.748, 0.904) and 0.759 (0.624, 0.865) respectively. Using the “per
250 patient” pairwise comparison approach, no significant difference in sensitivity was seen
251 between sputum and induced sputum. Using this approach, we found that the sensitivity of
252 bronchial aspirate, was significantly higher than BAL with respectively 0.974 (0.865, 0.999) and
253 0.564 (0.396, 0.722) (p. value 0.0003). The sensitivity of bronchial aspirate was also higher
254 than sputum with respectively 1 (0.753, 1) *versus* 0.385 (0.139, 0.684) (p-value = 0.017) (Table
255 5, S5 and S10).

256 These data suggest, no significant difference in the sensitivity of PCR between sputum and
257 induced sputum when the patient can produce spontaneous sputum. In contrast, bronchial
258 aspirate displays higher sensitivity than sputum and BAL. PCR displayed a high specificity for
259 all the respiratory specimens.

260

261 **3.6 Performance of culture according to the type of respiratory** 262 **specimen.**

263 Using the classical “per specimen” approach,—the sensitivity of culture when considering all
264 respiratory specimen was 0.988 (0.978, 0.994). The sensitivities of culture for sputum, induced
265 sputum, bronchial aspirate and BAL were 0.993 (0.981, 0.998), 0.980 (0.931, 0.998), 0.965
266 (0.919, 0.988), and 1 (0.961, 1).

267 Using the “per patient” comparison of paired specimens, no significant difference in sensitivity
268 was seen between the different respiratory specimens expect a superiority of bronchial aspirate
269 over BAL, 0.970 (0.914, 0.994) *versus* 0.636 (0.538, 0.731) (p. value < 0.0001) (Table 6, S6
270 and S11).

271

272 **4. Discussion**

273 The microbial diagnosis of tuberculosis is based on a combination of different microbiological
274 tests that can be performed on different types of clinical samples. We aimed to identify the
275 most efficient tests and specimen in order to guarantee an ideal sensitivity and specificity and
276 to limit the use of unnecessary tests.

277

278

279 **Smear independent diagnostic of tuberculosis**

280 Our results confirm a limited sensitivity of smear microscopy (0.523). The specificity (0.994)
281 remains high, probably because of the extremely low prevalence (0.036) of positive
282 microscopy. Our data suggest a higher sensitivity of microscopy on sputum over the three
283 other samples. This is probably a bias because patients for whom the microbiological
284 diagnosis is not made on spontaneous sputum and who therefore need induced sputum or
285 bronchial aspiration and BAL are patients with paucibacillary infections as previously reported
286 by Cadena et al [17]. Using a pairwise comparison method to avoid the patient effect, we do
287 not see any significant difference in sensitivity of microscopy between the various clinical
288 specimens. With a time to result lower than 30 minutes, microscopy remains virtually the
289 fastest diagnostic test. However, its sensitivity and specificity is limited and it requires a lot of
290 work by specialized personnel and the performance of this test may vary depending on the
291 experience of the examiner [8,18]. In a region with a low prevalence of tuberculosis, the
292 question arises of the usefulness of this test. In 2016, we introduced in our laboratory a smear-
293 independent algorithm for the diagnostic of tuberculosis [8]. For all the suspicion of
294 tuberculosis the microbial diagnosis is initiated by PCR; microscopy were not achieved
295 anymore in emergency but grouped once per day. In case of suspected pulmonary
296 tuberculosis, we initiated microbial diagnostic by the rapid molecular test Xpert MTB/RIF
297 further replaced by Xpert MTB/RIF Ultra which is used both to detect *M. tuberculosis* DNA
298 and to address patient infectiousness based on the semi-quantitative result; microscopic
299 analysis was still performed after treatment start, in particular to guide contact tracing and
300 des-isolation decisions [5,8,19]. Another study on the diagnosis of NTM infection also
301 suggested a limited added-value of microscopy when 16S broad range PCR for the detection
302 of NTM is available [18]. Our data suggested that microscopy might be useful only for patients
303 with a high pre-test probability of NTM infections, such as immunocompromised patients or
304 patients with clinical and radiological suspicion of having NTM lung disease. In February 2020,
305 we and other diagnostic laboratory experienced an important staff limitation triggered by the
306 SARS-CoV-2 pandemics. Indeed, during the first wave of the SARS-CoV-2 pandemic, the
307 biomedical technicians were reassigned for the management of the SARS-CoV-2 RT-PCR
308 tests. In this context, we had to rapidly identify all the unnecessary analysis among which was
309 smear microscopy. As an immediate response, we therefore push forward, in February 2020,
310 the smear independent algorithm for the diagnostic of mycobacterial infection. Since then,
311 microscopy for the detection of acid-fast bacilli is achieved only on specific request from

312 clinicians or for patients with a confirmed diagnostic of tuberculosis; indeed, microscopy can
313 be useful for treatment follow-up because PCR can remain positive for a long period in
314 patient's respiratory specimens even when a treatment is well conducted and for contact
315 tracing investigations. Microscopy in addition to pan-mycobacterial PCR can also be
316 requested when there is a high pre-test probability of NTM infection [18].

317

318 **Towards less cultures?**

319 PCR has improved the diagnostic of tuberculosis with a lower limit of detection than
320 microscopy and an increased specificity for PCR targeting specific *M. tuberculosis* DNA
321 sequences such as the IS6110. Culture, the oldest microbiological test for tuberculosis,
322 remains the reference method with the lowest limit of detection [2,3]. The performance of
323 mycobacterial culture, sensitivity (98.8%) and specificity (100%), was calculated using a
324 composite gold standard including all the microbiological tests as well as clinical data. We
325 reported few patients with positive PCR but negative culture. It will therefore be difficult to do
326 without culture. Further optimization strategies could be implemented by selecting the most
327 performant tests on the most efficient clinical samples regarding pulmonary tuberculosis.
328 Thus, we could consider only a combination of (i) samples for PCR-based diagnosis to have
329 short time to results coupled to (ii) a selection of samples to perform the culture warranted to
330 obtain strains for testing susceptibility towards anti-mycobacterial agents and also to
331 guarantee an optimal sensitivity (with delayed results).

332 When pulmonary tuberculosis is suspected, sputum is the usual specimen that is
333 collected. Regarding microscopy, as indicated above there is no significant difference
334 between the different types of clinical samples. On the other hand, with regard to PCR and
335 culture which are much more sensitive and reliable tests we observed differences between
336 the clinical specimens. When looking at sputum and induced sputum we do not see a
337 significant difference in terms of sensitivity for culture. Several studies reported an increased
338 sensitivity of induced sputum over sputum [20,21]. Using the classical approach or the
339 pairwise comparison in the same patient, we did not observe a significant increase in
340 sensitivity with induced sputum compared to spontaneous sputum. However, the pairwise
341 comparisons suggest an increase in the yield of positivity when performing the two specimens.
342 This conclusion should be confirmed by further studies. BAL and bronchial aspirate are
343 generally coupled. The pairwise comparison demonstrates that in the case of tuberculosis the
344 bronchial aspirate (97% of sensitivity) outcompete BAL (63.6% of sensitivity) suggesting a
345 limited added benefit of the BAL for the diagnosis of tuberculosis. Bronchial aspirate and BAL
346 are invasive, which make prospective studies hardly conceivable. Therefore, this retrospective
347 study, giving access to 3'570 pairwise comparison including these specimen provide
348 important data on their performance. Bronchoscopy is not only useful for tuberculosis
349 diagnosis but also to investigate other infectious or non-infectious disease [22]. For instance,
350 BAL is a very good specimen for the diagnostic of fungal infection such as *Pneumocystis*
351 *jirovecii* infections or *Aspergillus fumigatus* infection [23-25]. In view of these results, it is
352 important to consider bronchial aspiration for the diagnosis of tuberculosis, confirming
353 previous studies [26]. A first step would therefore be to always add a search for mycobacteria

354 on the bronchial aspiration when it is missing in laboratory order. This is what we
355 systematically do in our lab when it is missing. This study provides data for diagnostic
356 stewardship and guidance for physicians and clinical microbiology laboratories. Such data
357 could also help at defining diagnostic strategies in the setting of staff or reagents shortage or
358 to reduce costs. Indeed, even in low prevalence and high-income country, the infrastructure
359 and trained personnel for the diagnostic of tuberculosis is limited [27]. The SARS-CoV-2
360 pandemics negatively impacted tuberculosis control because of the mobilization of trained
361 staff for other activities or because of the disruption of the supply chain of reagents and
362 compounds for tuberculosis diagnostic and treatments [28,29]. In a context of shortage of
363 reagents or other material for mycobacterial culture like the one we encountered during the
364 COVID-19 pandemic, if a prioritization had to be made, it should be done for the benefit of
365 bronchial aspiration; but this should be decided together with the clinician that can help
366 guiding the decision by providing clinical information for each case.

367

368 **Limits of the study and perspectives**

369 Molecular diagnostic significantly improved the microbial diagnostic of tuberculosis, in
370 particular the initial diagnostic, but is not yet generalized worldwide [30], mainly for economical
371 reasons. To assess the real economic impact of the management of tuberculosis a cost-
372 benefit analysis for the full replacement of microscopy in favor of PCR should be performed
373 since this study demonstrates the effectiveness of PCR over microscopy [31]. Such analysis
374 should incorporate that, in hospital setting, patients might be isolated in specific negative
375 pressure chambers for the duration of the investigation. Such cost-benefit study should also
376 address the risk of nosocomial infection due to delayed diagnostic. Future studies should
377 account for the evolution in practices that may have occurred over the ten years (2008-2018)
378 of the study. It would be worthwhile to relate the data with the evolution of protocols and
379 guidelines that were introduced during the studied period in order not to only add diagnostic
380 tools but also to stop the not useful approaches. This study will also permit to address the
381 dependence between the tests results and many other parameters such as the number of
382 tests, the quality of the clinical specimens and patients characteristics. This will be particularly
383 useful for results interpretation, in particular negative results. Finally, this study is based on a
384 large amount of data over a long period, which was made possible by the fact that all the
385 microbial result are in our LIS since 1995. Although, it may not be the case even in high
386 income country labs, comparison of these results with those obtained at other medical centers
387 should be performed with the view of cross-validating the robustness of the present results.

388

389 **Conclusions**

390 This study demonstrates that many improvements have been made in the microbiological
391 diagnosis of tuberculosis. There is no doubt about the added value of molecular diagnosis
392 compared to microscopy to initiate the diagnosis of tuberculosis. The limit of a generalization
393 of independent algorithms in microscopy lies in the access to molecular diagnosis. New
394 technologies such as the GeneXpert, which are supposed to solve this problem, are not yet

395 generalized. Regarding tuberculosis, the limit in this case is not technological but again,
396 economical. This study provides data for diagnostic stewardship and for editing guidelines
397 and diagnosis protocols with the purpose to reduce the medical, social and economic costs
398 associated with tuberculosis. Indeed, even in low prevalence and high-income country, the
399 infrastructure and trained personnel for the diagnostic of tuberculosis is limited. Therefore,
400 there is a need to identify the most efficient tests and specimens in order to guarantee the
401 sensitivity and specificity and to limit the number of unnecessary tests. In addition, it provides
402 analytical strategies that may also be suitable for the study of other infectious diseases.
403

404 **5. Acknowledgements**

405 We are thankful to the Laboratory of Molecular Diagnostic and Mycobacteria of the Institute
406 of Microbiology of the University of Lausanne and Lausanne University Hospital that perform
407 the conventional and molecular analysis for the diagnosis of tuberculosis.
408

409 **6. References**

- 410
- 411 1 WHO. Global tuberculosis report 2021. 2021.
 - 412 2 van Zyl-Smit RN, Binder A, Meldau R, Mishra H, Semple PL, Theron G, et al.
413 Comparison of quantitative techniques including xpert mtb/rif to evaluate
414 mycobacterial burden. *PLOS ONE* 2011; **6**: e28815.
 - 415 3 Palomino JC. Nonconventional and new methods in the diagnosis of tuberculosis:
416 Feasibility and applicability in the field. *European Respiratory Journal* 2005; **26**: 339.
 - 417 4 Pfyffer GE, Wittwer F. Incubation time of mycobacterial cultures: How long is long
418 enough to issue a final negative report to the clinician? *Journal of clinical microbiology*
419 2012; **50**: 4188-9.
 - 420 5 Opota O, Zakham F, Mazza-Stalder J, Nicod L, Greub G, Jaton K. Added value of
421 xpert mtb/rif ultra for diagnosis of pulmonary tuberculosis in a low-prevalence setting.
422 *J Clin Microbiol* 2019; **57**.
 - 423 6 Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, et al. Rapid
424 molecular detection of tuberculosis and rifampin resistance. *N Engl J Med* 2010; **363**:
425 1005-15.
 - 426 7 Campelo TA, Cardoso de Sousa PR, Nogueira LL, Frota CC, Zuquim Antas PR.
427 Revisiting the methods for detecting mycobacterium tuberculosis: What has the new
428 millennium brought thus far? *Access Microbiol* 2021; **3**: 000245.
 - 429 8 Opota O, Senn L, Prod'hom G, Mazza-Stalder J, Tissot F, Greub G, et al. Added value
430 of molecular assay xpert mtb/rif compared to sputum smear microscopy to assess the
431 risk of tuberculosis transmission in a low-prevalence country. *Clin Microbiol Infect*
432 2016; **22**: 613-9.
 - 433 9 WHO. Who consolidated guidelines on tuberculosis module 3: Rapid diagnostics for
434 tuberculosis detection. 2021.
 - 435 10 WHO. Who consolidated guidelines on tuberculosis module 2: Screening, systematic
436 screening for tuberculosis disease. 2021.
 - 437 11 Greub G, Sahli R, Brouillet R, Jaton K. Ten years of r&d and full automation in
438 molecular diagnosis. *Future Microbiol* 2016; **11**: 403-25.
 - 439 12 Dorman SE, Schumacher SG, Alland D, Nabeta P, Armstrong DT, King B, et al. Xpert
440 mtb/rif ultra for detection of mycobacterium tuberculosis and rifampicin resistance: A
441 prospective multicentre diagnostic accuracy study. *Lancet Infect Dis* 2018; **18**: 76-84.
 - 442 13 Lippincott CK, Miller MB, Popowitch EB, Hanrahan CF, Van Rie A. Xpert mtb/rif assay

- 443 shortens airborne isolation for hospitalized patients with presumptive tuberculosis in
444 the united states. *Clin Infect Dis* 2014; **59**: 186-92.
- 445 14 Weiszhar Z, Horvath I. Induced sputum analysis: Step by step. *Breathe* 2013; **9**: 300.
- 446 15 Schaaf HS, Reuter H. Chapter 22 - practical approaches to ordering diagnostic tests.
447 In: Schaaf HS, Zumla AI, Grange JM, et al., eds. *Tuberculosis*. Edinburgh: W.B.
448 Saunders 2009; 216-26.
- 449 16 Chakravorty S, Simmons AM, Rownecki M, Parmar H, Cao Y, Ryan J, et al. The new
450 xpert mtb/rif ultra: Improving detection of mycobacterium tuberculosis and resistance
451 to rifampin in an assay suitable for point-of-care testing. *MBio* 2017; **8**.
- 452 17 Cadena AM, Fortune SM, Flynn JL. Heterogeneity in tuberculosis. *Nat Rev Immunol*
453 2017; **17**: 691-702.
- 454 18 Andenmatten S, Opota O, Mazza-Stalder J, Nicod L, Greub G, Jaton K. Added
455 diagnostic value of 16s rrna gene pan-mycobacterial pcr for nontuberculous
456 mycobacterial infections: A 10-year retrospective study. *Eur J Clin Microbiol Infect Dis*
457 2019.
- 458 19 Opota O, Mazza-Stalder J, Greub G, Jaton K. The rapid molecular test xpert mtb/rif
459 ultra: Towards improved tuberculosis diagnosis and rifampicin resistance detection.
460 *Clin Microbiol Infect* 2019; **25**: 1370-6.
- 461 20 Biswas S, Das A, Sinha A, Das SK, Bairagya TD. The role of induced sputum in the
462 diagnosis of pulmonary tuberculosis. *Lung India : official organ of Indian Chest Society*
463 2013; **30**: 199-202.
- 464 21 Seong GM, Lee J, Lee JH, Kim JH, Kim M. Usefulness of sputum induction with
465 hypertonic saline in a real clinical practice for bacteriological yields of active pulmonary
466 tuberculosis. *Tuberculosis and respiratory diseases* 2014; **76**: 163-8.
- 467 22 Sanjeevaiah S, Haranal MY, Buggi S. Role of flexible bronchoscopy in patients with
468 sputum-negative pulmonary tuberculosis. *Indian journal of thoracic and cardiovascular*
469 *surgery* 2018; **34**: 365-9.
- 470 23 Imbert S, Meyer I, Palous M, Brossas J-Y, Uzunov M, Touafek F, et al. Aspergillus pcr
471 in bronchoalveolar lavage fluid for the diagnosis and prognosis of aspergillosis in
472 patients with hematological and non-hematological conditions. *Frontiers in*
473 *microbiology* 2018; **9**: 1877-.
- 474 24 Neofytos D, Garcia-Vidal C, Lamoth F, Lichtenstern C, Perrella A, Vehreschild JJ.
475 Invasive aspergillosis in solid organ transplant patients: Diagnosis, prophylaxis,
476 treatment, and assessment of response. *BMC Infect Dis* 2021; **21**: 296.
- 477 25 Perret T, Kritikos A, Hauser PM, Guiver M, Coste AT, Jaton K, et al. Ability of
478 quantitative pcr to discriminate pneumocystis jirovecii pneumonia from colonization. *J*
479 *Med Microbiol* 2020; **69**: 705-11.
- 480 26 Maitre T, Ok V, Morel F, Bonnet I, Sougakoff W, Robert J, et al. Sampling strategy for
481 bacteriological diagnosis of intrathoracic tuberculosis. *Respir Med Res* 2021; **79**:
482 100825.
- 483 27 Cannas A, Paglia MG, Sakhoo DC, Vairo F, Doulla B, Nguhuni B, et al. Strengthening
484 tuberculosis diagnosis in a low-resource setting: Experience learned in dodoma,
485 tanzania. *J Infect Dev Ctries* 2013; **7**: 676-9.
- 486 28 Armstrong DT, Tacheny EA, Olinger G, Howard R, Lemmon MM, Dasgupta D, et al.
487 Sars-cov-2 supply shortages and tuberculosis diagnostics: Current issues requiring
488 immediate solutions. *J Clin Microbiol* 2021; **59**: e0077821.
- 489 29 Meneguim AC, Rebello L, Das M, Ravi S, Mathur T, Mankar S, et al. Adapting tb
490 services during the covid-19 pandemic in mumbai, india. *Int J Tuberc Lung Dis* 2020;
491 **24**: 1119-21.
- 492 30 Mechai F, Cordel H, Guglielmetti L, Aubry A, Jankovic M, Viveiros M, et al.
493 Management of tuberculosis: Are the practices homogeneous in high-income
494 countries? *Front Public Health* 2020; **8**: 443.
- 495 31 Dowdy DW, Houben R, Cohen T, Pai M, Cobelens F, Vassall A, et al. Impact and cost-
496 effectiveness of current and future tuberculosis diagnostics: The contribution of
497 modelling. *The international journal of tuberculosis and lung disease : the official*
498 *journal of the International Union against Tuberculosis and Lung Disease* 2014; **18**:

499 1012-8.
500
501

502 7. Tables

503
504 **Table 1. Performance of smear microscopy for the diagnostic of**
505 **pulmonary tuberculosis according of the type of specimen.**

506
507

Table 1. Performance of smear microscopy for the diagnostic of pulmonary tuberculosis according of the type of specimen.

	Accuracy	Sensitivity	Specificity	Prevalence	PPV	NPV
All specimens	0.977 (0.975, 0.979) 23219/23763	0.523 (0.489, 0.557) 447/855	0.994 (0.993, 0.995) 22772/22908	0.036 (0.034, 0.038) 855/23763	0.767 (0.730, 0.800) 447/583	0.982 (0.981, 0.984) 22772/23180
Sputum	0.967 (0.963, 0.971) 8132/8409	0.605 (0.562, 0.647) 320/529	0.991 (0.989, 0.993) 7812/7880	0.063 (0.058, 0.068) 529/8409	0.825 (0.783, 0.861) 320/388	0.974 (0.970, 0.977) 7812/8021
Induced sputum	0.966 (0.957, 0.973) 2119/2194	0.362 (0.265, 0.467) 34/94	0.993 (0.988, 0.996) 2085/2100	0.043 (0.035, 0.052) 94/2194	0.694 (0.546, 0.817) 34/49	0.972 (0.964, 0.979) 2085/2194
Bronchial aspirate	0.985 (0.982, 0.988) 8463/8591	0.362 (0.283, 0.447) 51/141	0.996 (0.994, 0.997) 8412/8450	0.016 (0.014, 0.019) 141/8591	0.573 (0.464, 0.677) 51/89	0.989 (0.987, 0.991) 8412/8502
BAL	0.986 (0.982, 0.989) 4505/4569	0.462 (0.356, 0.569) 42/91	0.997 (0.994, 0.998) 4463/4478	0.020 (0.016, 0.024) 91/4569	0.737 (0.603, 0.845) 42/57	0.989 (0.986, 0.992) 4463/4512

All p.values in supplementary material.

508
509

510
511 **Table 2. Performance of PCR for the diagnostic of pulmonary**
512 **tuberculosis according to the type of specimen.**

513

Table 2. Performance of PCR for the diagnostic of pulmonary tuberculosis according to the type of specimen.

	Accuracy	Sensitivity	Specificity	Prevalence	PPV	NPV
All specimens	0.988 (0.986, 0.991) 7009/7091	0.798 (0.755, 1) 0.836) 320/401	1 (0.999, 1) 6689/6690	0.057 (0.051, 1) 0.062) 401/7091	0.997 (0.983, 1) 1) 320/321	0.988 (0.985, 0.990) 0.990) 6770/7091
All specimens smear microscopy negative	0.988 (0.985, 0.991) 6982/7066	0.585 (0.513, 0.654) 117/200	1 (0.999, 1) 6865/6866	0.028 (0.025, 0.032) 200/7066	0.992 (0.954, 1) 117/118	0.988 (0.985, 0.990) 6865/6948
All specimens smear microscopy positive	1 (0.987, 1) 286/286	1 (0.983, 1) 210/210	1 (0.953, 1) 76/76	0.734 (0.679, 0.785) 210/286	1 (0.983, 1) 1) 210/210	1 (0.953, 1) 1) 76/76
Sputum	0.986 (0.980, 0.990) 2525/2562	0.821 (0.762, 0.871) 170/207	>0.999 (0.998, 1) 2355/2355	0.081 (0.071, 1) 0.092) 207/2562	1 (0.979, 1) 170/170	0.985 (0.979, 0.989) 0.989) 2355/2562
Induced sputum	0.977 (0.962, 0.987) 636/651	0.643 (0.480, 0.784) 27/42	>0.999 (0.994, 1) 609/609	0.065 (0.047, 1) 0.086) 42/609	1 (0.872, 1) 27/27	0.976 (0.961, 0.986) 0.986) 609/624
Bronchial aspirate	0.993 (0.988, 0.996) 2256/2273	0.837 (0.748, 0.904) 82/98	>0.999 (0.997, 1) 2174/2175	0.043 (0.035, 1) 0.052) 98/2273	0.988 (0.935, 1) 1) 82/83	0.993 (0.988, 0.996) 0.996) 2174/2175
BAL	0.992 (0.986, 0.996) 1592/1605	0.759 (0.624, 0.865) 41/54	>0.999 (0.914, 1) 1551/1551	0.034 (0.025, 1) 0.044) 54/1605	1 (0.914, 1) 41/41	0.992 (0.986, 0.996) 0.996) 1551/1564

All p.values in supplementary material

514

515

516 **Table 3: Performance of culture for the diagnostic of pulmonary**
 517 **tuberculosis according to the type of specimen.**
 518

Table 3: Performance of culture for the diagnostic of pulmonary tuberculosis according to the type of specimen.

	Accuracy	Sensitivity	Specificity	Prevalence	PPV	NPV
All specimens	>0.999 (0.999, 1) 24019/24030	0.988 (0.978, 0.994) 871/882	1 (1, 1) 23148/23148	0.037 (0.034, 0.039) 882/24030	1 (0.996, 1) 871/871	1 (0.999, 1) 23148/23159
Sputum	>0.999 (0.999, 1) 8583/8587	0.993 (0.981, 0.998) 543/547	1 (1, 1) 8040/8040	0.064 (0.059, 0.069) 547/8587	1 (0.993, 1) 543/543	1 (0.999, 1) 8040/8044
Induced sputum	1 (0.997, 1) 2255/2257	0.980 (0.931, 0.998) 100/102	1 (0.998, 1) 2155/2155	0.045 (0.037, 0.055) 102/2155	1 (0.964, 1) 100/100	1 (0.997, 1) 2155/2157
Bronchial aspirate	>0.999 (0.999, 1) 8605/8610	0.965 (0.919, 0.988) 136/141	1 (1, 1) 8469/8469	0.016 (0.014, 0.019) 141/8610	1 (0.973, 1) 136/136	0.999 (0.999, 1) 8469/8474
BAL	1 (0.999, 1) 4576/4576	1 (0.961, 1) 92/92	1 (0.999, 1) 4484/4484	0.020 (0.016, 0.025) 92/4576	1 (0.961, 1) 92/92	1 (0.999, 1) 4484/4484

All p.values in supplementary material

519
520

521 **Table 4. Sensitivity of microscopy to predict tuberculosis according**
 522 **to the type of specimen using a 72-hours pairing window in the same**
 523 **patient.**

524
 525

Table 4. Sensitivity of microscopy to predict tuberculosis according to the type of specimen using a 72-hours pairing window in the same patient.		
	Sensitivity	NPV
Sputum versus induced sputum		
Sputum	0.923 (0.640, 0.998) 12/13 ^{n.s}	0.997 (0.986, 1) 390/391 ^{n.s}
Induced Sputum	0.769 (0.462, 0.950) 10/13 ^{n.s}	0.992 (0.978, 0.998) 390/393 ^{n.s}
Sputum versus bronchial aspirate		
Sputum	0.692 (0.386, 0.909) 9/13 ^{n.s}	0.988 (0.970, 0.997) 337/341 ^{n.s}
Bronchial aspirate	0.846 (0.546, 0.981) 11/13 ^{n.s}	0.994 (0.979, 0.999) 337/339 ^{n.s}
Sputum versus BAL		
Sputum	1 (0.631, 1) 8/8 ^{n.s}	1 (0.987, 1) 280/280 ^{n.s}
BAL	0.750 (0.349, 0.968) 6/8 ^{n.s}	0.993 (0.975, 0.999) 280/282 ^{n.s}
Induced sputum versus bronchial aspirate		
Induced Sputum	0.500 (0.013, 0.987) 1/2 ^{n.s}	0.982 (0.904, 1) 55/56 ^{n.s}
Bronchial aspirate	0.500 (0.013, 0.987) 1/2 ^{n.s}	0.982 (0.904, 1) 55/56 ^{n.s}
Induced sputum versus BAL		
Induced Sputum	0.333 (0.008, 0.906) 1/3 ^{n.s}	0.962 (0.868, 0.995) 50/52 ^{n.s}
BAL	0.667 (0.094, 0.992) 2/3 ^{n.s}	0.980 (0.896, 1) 50/51 ^{n.s}
Bronchial aspirate versus BAL		
Bronchial aspirate	0.881 (0.744, 0.960) 37/42 ^{n.s}	0.999 (0.997, 1.000) 3528/3533 ^{n.s}
BAL	0.714 (0.554, 0.843) 30/42 ^{n.s}	0.997 (0.994, 0.998) 3528/3540 ^{n.s}
All p.values in supplementary material		

526
 527
 528
 529
 530

531 **Table 5. Sensitivity of PCR to predict tuberculosis according to the**
 532 **type of specimen using a 72-hours pairing window in the same**
 533 **patient.**

534
 535

Table 5. Sensitivity of PCR to predict tuberculosis according to the type of specimen using a 72-hours pairing window in the same patient.		
	Sensitivity	NPV
Sputum versus induced sputum		
Sputum	0.667 (0.094, 0.992) 2/3 ^{n.s}	0.992 (0.958, 1) 129/130 ^{n.s}
Induced sputum	0.667 (0.094, 0.992) 2/3 ^{n.s}	0.992 (0.958, 1) 129/130 ^{n.s}
Sputum versus bronchial aspirate		
Sputum	0.385 (0.139, 0.684) 5/13 *	0.953 (0.909, 0.979) 161/169 ^{n.s}
Bronchial aspirate	1 (0.753, 1) 13/13 *	1 (0.977, 1) 161/161 ^{n.s}
Sputum versus BAL		
Sputum	0.600 (0.147, 0.947) 3/5 ^{n.s}	0.985 (0.947, 0.998) 132/134 ^{n.s}
BAL	1 (0.478, 1) 5/5 ^{n.s}	1 (0.478, 1) 132/132 ^{n.s}
Induced sputum versus bronchial aspirate		
Induced sputum	0.857 (0.421, 0.996) 6/7 ^{n.s}	0.968 (0.833, 0.999) 30/31 ^{n.s}
Bronchial aspirate	0.714 (0.290, 0.963) 5/7 ^{n.s}	0.938 (0.792, 0.992) 30/32 ^{n.s}
Induced sputum versus BAL		
Induced sputum	1 (0.478, 1) 5/5 ^{n.s}	1 (0.884, 1) 30/30 ^{n.s}
BAL	0.600 (0.147, 0.947) 3/5 ^{n.s}	0.938 (0.792, 0.992) 30/32 ^{n.s}
Bronchial aspirate versus BAL		
Bronchial aspirate	0.974 (0.865, 0.999) 38/39 ***	0.999 (0.995, 1.000) 1142/1143 **
BAL	0.564 (0.396, 0.722) 22/39 ***	0.985 (0.977, 0.991) 1142/1159 **
All p.values in supplementary material		

536
 537

538 **Table 6. Sensitivity of culture to predict tuberculosis according to**
 539 **the type of specimen using a 72-hours pairing window within the**
 540 **same patient.**

541
 542

Table 6. Sensitivity of culture to predict tuberculosis according to the type of specimen using a 72-hours pairing window within the same patient.		
	Sensitivity	NPV
Sputum versus induced sputum		
Sputum	0.857 (0.697, 0.952) 30/35 ^{n.s}	0.987 (0.969, 0.996) 368/373 ^{n.s}
Induced sputum	0.800 (0.631, 0.916) 28/35 ^{n.s}	0.981 (0.962, 0.992) 368/375 ^{n.s}
Sputum versus bronchial aspirate		
Sputum	0.613 (0.422, 0.782) 19/31 ^{n.s}	0.964 (0.937, 0.981) 318/330 ^{n.s}
Bronchial aspirate	0.903 (0.742, 0.980) 28/31 ^{n.s}	0.991 (0.973, 0.998) 318/321 ^{n.s}
Sputum versus BAL		
Sputum	0.895 (0.669, 0.987) 17/19 ^{n.s}	0.993 (0.974, 0.999) 268/270 ^{n.s}
BAL	0.789 (0.544, 0.939) 15/19 ^{n.s}	0.985 (0.963, 0.996) 268/272 ^{n.s}
Induced sputum versus bronchial aspirate		
Induced sputum	0.692 (0.386, 0.909) 9/13 ^{n.s}	0.915 (0.796, 0.976) 43/47 ^{n.s}
Bronchial aspirate	0.846 (0.546, 0.981) 11/13 ^{n.s}	0.956 (0.849, 0.995) 43/45 ^{n.s}
Induced sputum versus BAL		
Induced sputum	0.769 (0.462, 0.950) 10/13 ^{n.s}	0.929 (0.805, 0.985) 39/42 ^{n.s}
BAL	0.462 (0.192, 0.749) 6/13 ^{n.s}	0.848 (0.711, 0.937) 39/46 ^{n.s}
Bronchial aspirate versus BAL		
Bronchial aspirate	0.970 (0.914, 0.994) 96/99 ^{***}	0.999 (0.997, 1.000) 3471/3474 ^{***}
BAL	0.636 (0.538, 0.731) 63/99 ^{***}	0.990 (0.986, 0.993) 3471/3507 ^{***}
All p.values details in supplementary material		

543
 544

545
546
547
548
549

8. Supplementary material

Table S1. P-values for Table 1, performance of smear microscopy according of the type of specimen.

MICROSCOPY	Sample1	Sample2	Diff_1m2	p.val	adj.p.val	sig.code
ACCURACY	All specimens	Sputum	0.01004816	6.31016E-07	6.3102E-06	***
ACCURACY	All specimens	Induced sputum	0.01129141	0.00118018	0.0118018	*
ACCURACY	All specimens	Bronchial aspirate	0.0079934	1.04282E-05	0.00010428	***
ACCURACY	All specimens	BAL	0.0088853	0.00018404	0.0018404	**
ACCURACY	Sputum	Induced sputum	0.00124324	0.82387393	0.82387393	n.s.
ACCURACY	Sputum	Bronchial aspirate	0.0180416	1.83229E-14	1.8323E-13	***
ACCURACY	Sputum	BAL	0.0189335	1.73634E-10	1.7363E-09	***
ACCURACY	Induced sputum	Bronchial aspirate	0.0192848	5.08274E-09	5.0827E-08	***
ACCURACY	Induced sputum	BAL	0.0201767	7.30806E-08	7.3081E-07	***
ACCURACY	Bronchial aspirate	BAL	0.0008919	0.74149137	0.74149137	n.s.
SENSITIVITY	All specimens	Sputum	0.0821079	0.00338320	0.0338320	*
SENSITIVITY	All specimens	Induced sputum	0.16110489	0.00427942	0.0427942	*
SENSITIVITY	All specimens	Bronchial aspirate	0.16110489	0.00055236	0.0055236	**
SENSITIVITY	All specimens	BAL	0.06126856	0.31654015	0.31654015	n.s.
SENSITIVITY	Sputum	Induced sputum	0.24321281	1.92189E-05	0.0001921	***
SENSITIVITY	Sputum	Bronchial aspirate	0.24321281	4.0431E-07	4.04E-06	***
SENSITIVITY	Sputum	BAL	0.14337647	0.01436764	0.1436764	n.s.
SENSITIVITY	Induced sputum	Bronchial aspirate	0.0998363	0.21854228	0.21854228	n.s.
SENSITIVITY	Induced sputum	BAL	0.0998363	0.16826052	0.16826052	n.s.
SENSITIVITY	Bronchial aspirate	BAL	0.0998363	0.0026926	0.01386013	n.s.
SPECIFICITY	All specimens	Sputum	0.00120605	0.01386013	0.1386013	n.s.
SPECIFICITY	All specimens	Induced sputum	0.00120607	0.59219501	0.59219501	n.s.
SPECIFICITY	All specimens	Bronchial aspirate	0.0014397	0.15068156	0.15068156	n.s.
SPECIFICITY	All specimens	BAL	0.0025871	0.0014397	0.04256828	n.s.
SPECIFICITY	Sputum	Induced sputum	0.0014866	0.04256828	0.4256828	n.s.
SPECIFICITY	Sputum	BAL	0.0014866	0.59517745	0.59517745	n.s.
SPECIFICITY	Sputum	Induced sputum	0.0014866	0.0014866	0.0014866	n.s.

	Sputum	Bronchial aspirate	-	0.00143062	0.0143062	
SPECIFICITY			0.0041324	3	3	*
	Sputum	BAL	0.0052797	2	2	**
SPECIFICITY	Induced sputum	Bronchial aspirate	0.0026458	7	1	n.s.
	Induced sputum	BAL	0.0037931	3	3	n.s.
SPECIFICITY	Bronchial aspirate	BAL	0.0011473	9	1	n.s.
PREVALENC E	All specimens	Sputum	0.0269285	25	1.841E-24	***
PREVALENC E	All specimens	Induced sputum	0.0068638	0.11419982	1	n.s.
PREVALENC E	All specimens	Bronchial aspirate	0.0195677	8	3.18425E-19	3.1843E-18 ***
PREVALENC E	All specimens	BAL	0.0160634	7	4.01497E-08	4.015E-07 ***
PREVALENC E	Sputum	Induced sputum	0.0200646	7	0.00045144	0.0045144
PREVALENC E	Sputum	Bronchial aspirate	0.0464962	6	1.90752E-54	1.9075E-53 ***
PREVALENC E	Sputum	BAL	0.0429919	6	8.81979E-28	8.8198E-27 ***
PREVALENC E	Induced sputum	Bronchial aspirate	0.0264316	7	7.06582E-14	7.0658E-13 ***
PREVALENC E	Induced sputum	BAL	0.0229272	9	9.71951E-08	9.7195E-07 ***
PREVALENC E	Bronchial aspirate	BAL	0.0035043	-	0.16613582	1
NPV	All specimens	Sputum	0.0084552	2	3.45875E-06	3.4587E-05 ***
NPV	All specimens	Induced sputum	0.0320795	7	6.34282E-24	6.3428E-23 ***
NPV	All specimens	Bronchial aspirate	0.0070156	-	1.09507E-05	0.0001095
NPV	All specimens	BAL	0.0067415	-	0.00143193	0.0143193
NPV	Sputum	Induced sputum	0.0236243	5	2.45115E-08	2.4512E-07 ***
NPV	Sputum	Bronchial aspirate	0.0154709	-	1.38418E-13	1.3842E-12 ***
NPV	Sputum	BAL	0.0151967	-	1.30343E-08	1.3034E-07 ***
NPV	Induced sputum	Bronchial aspirate	0.0390952	-	3.82866E-33	3.8287E-32 ***
NPV	Induced sputum	BAL	-0.038821	8	1.88248E-22	1.8825E-21 ***
NPV	Bronchial aspirate	BAL	0.0002741	8	0.95595959	5
PPV	All specimens	Sputum	0.0580184	-	0.03631775	0.3631775
PPV	All specimens	Induced sputum	0.0728462	9	0.32999978	9
PPV	All specimens	Bronchial aspirate	0.1936901	3	0.00017301	0.0017301
PPV	All specimens	BAL	0.0298817	4	0.73106541	7
PPV	Sputum	Induced sputum	0.1308647	2	0.04471574	0.4471574
PPV	Sputum	Bronchial aspirate	0.2517085	6	5.44063E-07	5.4406E-06 ***

PPV	Sputum	BAL	0.0879001	0.15890288		
		Bronchial aspirate	6	6	1	n.s.
PPV	Induced sputum	BAL	0.1208438	0.22480548		
		Bronchial aspirate	4	1	1	n.s.
PPV	Induced sputum	BAL	-	0.78458139		
		Bronchial aspirate	0.0429646	4	1	n.s.
PPV	Bronchial aspirate	BAL	-	0.06700905	0.6700905	
		BAL	0.1638084	1	1	n.s.

550

551

552 **Table S2. P-values for Table 2, performance of PCR according of the**
553 **type of specimen.**

PCR	Sample1	Sample2	Diff_1m2	p.val	adj.p.val	sig.code
ACCURACY	All specimens	Sputum	0.00287789	0.304418176	1	n.s.
ACCURACY	All specimens	Induced sputum	0.01147752	0.019512972	0.19512972	n.s.
ACCURACY	All specimens	Bronchial aspirate	-0.0040849	0.123765813	1	n.s.
ACCURACY	All specimens	BAL	-0.0034643	0.283404464	1	n.s.
ACCURACY	Sputum	Induced sputum	0.00859963	0.167946429	1	n.s.
ACCURACY	Sputum	Bronchial aspirate	-0.0069627	0.030595877	0.30595877	n.s.
ACCURACY	Sputum	BAL	-0.0063422	0.092258909	0.92258909	n.s.
ACCURACY	Induced sputum	Bronchial aspirate	-0.0155624	0.001625285	0.01625285	*
ACCURACY	Induced sputum	BAL	-0.0149418	0.007047431	0.07047431	n.s.
ACCURACY	Bronchial aspirate	BAL	0.00062059	0.975120507	1	n.s.
SENSITIVITY	All specimens	Sputum	-0.0232511	0.562771431	1	n.s.
SENSITIVITY	All specimens	Induced sputum	0.15514784	0.033580028	0.33580028	n.s.
SENSITIVITY	All specimens	Bronchial aspirate	-0.0387297	0.467749275	1	n.s.
SENSITIVITY	All specimens	BAL	0.03874573	0.630382277	1	n.s.
SENSITIVITY	Sputum	Induced sputum	0.1783989	0.017069317	0.17069317	n.s.
SENSITIVITY	Sputum	Bronchial aspirate	-0.0154787	0.863947971	1	n.s.
SENSITIVITY	Sputum	BAL	0.06199678	0.402691103	1	n.s.
SENSITIVITY	Induced sputum	Bronchial aspirate	-0.1938776	0.020902399	0.20902399	n.s.
SENSITIVITY	Induced sputum	BAL	-0.1164021	0.308470102	1	n.s.
SENSITIVITY	Bronchial aspirate	BAL	0.07747543	0.343242299	1	n.s.
SPECIFICITY	All specimens	Sputum	-0.0001495	1	1	n.s.
SPECIFICITY	All specimens	Induced sputum	-0.0001495	1	1	n.s.
SPECIFICITY	All specimens	Bronchial aspirate	-0.0001495	1	1	n.s.
SPECIFICITY	All specimens	BAL	-0.0001495	1	1	n.s.
SPECIFICITY	Sputum	Induced sputum	0	NA	NA	
SPECIFICITY	Sputum	Bronchial aspirate	0	NA	NA	
SPECIFICITY	Sputum	BAL	0	NA	NA	
SPECIFICITY	Induced sputum	Bronchial aspirate	0	NA	NA	
SPECIFICITY	Induced sputum	BAL	0	NA	NA	
SPECIFICITY	Bronchial aspirate	BAL	0	NA	NA	
PREVALENC E	All specimens	Sputum	-0.0242457	1.85046E-05	0.00018505	***
PREVALENC E	All specimens	Induced sputum	-0.012415	0.24121711	1	n.s.
PREVALENC E	All specimens	Bronchial aspirate	0.01343573	0.015178942	0.15178942	n.s.

PREVALENC E	All specimens	BAL	0.0229057	0.000252936	0.00252936	**
PREVALENC E	Sputum	Induced sputum	0.01183074	0.372502519		1 n.s.
PREVALENC E	Sputum	Bronchial aspirate	0.03768143	1.03816E-07	1.0382E-06	***
PREVALENC E	Sputum	BAL	0.04715139	1.47378E-09	1.4738E-08	***
PREVALENC E	Induced sputum	Bronchial aspirate	0.02585069	0.011433057	0.11433057	n.s.
PREVALENC E	Induced sputum	BAL	0.03532066	0.000420219	0.00420219	**
PREVALENC E	Bronchial aspirate	BAL	0.00946997	0.157733443		1 n.s.
NPV	All specimens	Sputum	0.0355276	1.72723E-11	1.7272E-10	***
NPV	All specimens	Induced sputum	-0.0212302	0.016901135	0.16901135	n.s.
NPV	All specimens	Bronchial aspirate	-0.0448089	3.59424E-23	3.5942E-22	***
NPV	All specimens	BAL	-0.0369566	1.0787E-11	1.0787E-10	***
NPV	Sputum	Induced sputum	-0.0567578	9.29799E-07	9.298E-06	***
NPV	Sputum	Bronchial aspirate	-0.0803365	8.28082E-41	8.2808E-40	***
NPV	Sputum	BAL	-0.0724842	1.81678E-23	1.8168E-22	***
NPV	Induced sputum	Bronchial aspirate	-0.0235787	4.52576E-11	4.5258E-10	***
NPV	Induced sputum	BAL	-0.0157264	0.006062577	0.06062577	n.s.
NPV	Bronchial aspirate	BAL	0.00785225	0.00031041	0.0031041	**
PPV	All specimens	Sputum	-0.0031153		1	1 n.s.
PPV	All specimens	Induced sputum	-0.0031153		1	1 n.s.
PPV	All specimens	Bronchial aspirate	-0.0031153		1	1 n.s.
PPV	All specimens	BAL	-0.0031153		1	1 n.s.
PPV	Sputum	Induced sputum		0	NA	NA
PPV	Sputum	Bronchial aspirate		0	NA	NA
PPV	Sputum	BAL		0	NA	NA
PPV	Induced sputum	Bronchial aspirate		0	NA	NA
PPV	Induced sputum	BAL		0	NA	NA
PPV	Bronchial aspirate	BAL		0	NA	NA

555 **Table S3. P-values for Table 3, performance of culture according of**
 556 **the type of specimen.**
 557

CULTURE	Sample1	Sample2	Diff_1m2	p.val	adj.p.val	sig.cod e
ACCURACY	All specimens	Sputum	8.0593E-06	1	1	n.s.
	All specimens		0.0004283	0.7038940		
ACCURACY		Induced sputum	7	2	1	n.s.
	All specimens	Bronchial aspirate	0.0001229			
ACCURACY			6	0.8740244	1	n.s.
	All specimens			0.3000820		
ACCURACY		BAL	-0.0004578	1	1	n.s.
	Sputum		0.0004203	0.8005180		
ACCURACY		Induced sputum	1	8	1	n.s.
	Sputum	Bronchial aspirate	0.0001149	1	1	n.s.
	Sputum			0.3496985		
ACCURACY		BAL	-0.0004658	5	1	n.s.
				0.9656915		
ACCURACY	Induced sputum	Bronchial aspirate	-0.0003054	9	1	n.s.
				0.2068947		
ACCURACY	Induced sputum	BAL	-0.0008861	2	1	n.s.
	Bronchial aspirate			0.2457923		
ACCURACY		BAL	-0.0005807	2	1	n.s.
				0.5072520		
SENSITIVITY	All specimens	Sputum	-0.005159	4	1	n.s.
	All specimens		0.0071361	0.8889537		
SENSITIVITY		Induced sputum	9	6	1	n.s.
	All specimens	Bronchial aspirate	0.0229893	0.0934731	0.9347319	
SENSITIVITY			4	9	3	n.s.
	All specimens			0.5762589		
SENSITIVITY		BAL	-0.0124717	7	1	n.s.
	Sputum		0.0122952	0.5301970		
SENSITIVITY		Induced sputum	3	2	1	n.s.
	Sputum	Bronchial aspirate	0.0281483	0.0272888	0.2728883	
SENSITIVITY			8	3	5	n.s.
	Sputum			0.9136470		
SENSITIVITY		BAL	-0.0073126	2	1	n.s.
			0.0158531			
SENSITIVITY	Induced sputum	Bronchial aspirate	5	0.7334086	1	n.s.
SENSITIVITY	Induced sputum	BAL	-0.0196078	0.5232443	1	n.s.
				0.1727312		
SENSITIVITY	Bronchial aspirate	BAL	-0.035461	5	1	n.s.
SPECIFICITY	All specimens	Sputum	0	NA	NA	
SPECIFICITY	All specimens	Induced sputum	0	NA	NA	
SPECIFICITY	All specimens	Bronchial aspirate	0	NA	NA	
SPECIFICITY	All specimens	BAL	0	NA	NA	
SPECIFICITY	Sputum	Induced sputum	0	NA	NA	
SPECIFICITY	Sputum	Bronchial aspirate	0	NA	NA	

SPECIFICITY	Sputum	BAL	0	NA	NA	
SPECIFICITY	Induced sputum	Bronchial aspirate	0	NA	NA	
SPECIFICITY	Induced sputum	BAL	0	NA	NA	
SPECIFICITY	Bronchial aspirate	BAL	0	NA	NA	
PREVALENC						
E	All specimens	Sputum	-0.0269968	1.3127E-25	1.3127E-24	***
PREVALENC	All specimens			0.0152636	0.1526368	
E		Induced sputum	-0.0106277	8	1	n.s.
PREVALENC	All specimens	Bronchial aspirate	0.0203278			
E			1	2.1937E-20	2.1937E-19	***
PREVALENC	All specimens		0.0165992			
E		BAL	2	1.7986E-08	1.7986E-07	***
PREVALENC	Sputum		0.0163691	0.0050946	0.0509465	
E		Induced sputum	6	6	9	n.s.
PREVALENC	Sputum	Bronchial aspirate	0.0473246			
E			4	3.3813E-56	3.3813E-55	***
PREVALENC	Sputum		0.0435960			
E		BAL	5	2.4327E-28	2.4327E-27	***
PREVALENC		Bronchial aspirate	0.0309554			
E	Induced sputum		8	1.0264E-17	1.0264E-16	***
PREVALENC			0.0272268			
E	Induced sputum	BAL	9	7.7062E-10	7.7062E-09	***
PREVALENC	Bronchial aspirate			0.1395297		
E		BAL	-0.0037286	8	1	n.s.
NPV	All specimens	Sputum	2.2288E-05	1	1	n.s.
	All specimens			0.6371934		
NPV		Induced sputum	-0.000475	4	1	n.s.
	All specimens	Bronchial aspirate	0.0001150	0.9038903		
NPV			6	1	1	n.s.
	All specimens			0.2934213		
NPV		BAL	-0.000475	1	1	n.s.
	Sputum			0.6723950		
NPV		Induced sputum	-0.0004973	9	1	n.s.
	Sputum	Bronchial aspirate	9.2775E-05	1	1	n.s.
	Sputum			0.3311067		
NPV		BAL	-0.0004973	5	1	n.s.
		Bronchial aspirate	0.0005900	0.5676023		
NPV	Induced sputum		4	6	1	n.s.
NPV	Induced sputum	BAL	0	NA	NA	
	Bronchial aspirate			0.2473768		
NPV		BAL	-0.00059	8	1	n.s.
PPV	All specimens	Sputum	0	NA	NA	
PPV	All specimens	Induced sputum	0	NA	NA	
PPV	All specimens	Bronchial aspirate	0	NA	NA	
PPV	All specimens	BAL	0	NA	NA	
PPV	Sputum	Induced sputum	0	NA	NA	
	Sputum	Bronchial aspirate	0	NA	NA	
PPV	Sputum	BAL	0	NA	NA	

PPV	Induced sputum	Bronchial aspirate	0	NA	NA
PPV	Induced sputum	BAL	0	NA	NA
PPV	Bronchial aspirate	BAL	0	NA	NA

558

559 **Table S4. P-values for Table 4, performance of smear microscopy**
 560 **according of the type of specimen.**
 561

Table S4. P-values for table 4, performance of smear microscopy according of the type of specimen.

Pairwise Comparison Direct						
Exam	Sample1	Sample2	Diff_1m2	p.val	adj.p.val	sig.code
SENSITIVITY	Sputum	Induced sputum	0.15384615	0.58674615	1	n.s.
SENSITIVITY	Sputum	Bronchial aspirate	-0.1538462	0.64159157	1	n.s.
SENSITIVITY	Sputum	BAL	0.25	0.4496918	1	n.s.
SENSITIVITY	Induced sputum	Bronchial aspirate	0	1	1	n.s.
SENSITIVITY	Induced sputum	BAL	-0.3333333	1	1	n.s.
SENSITIVITY	Bronchial aspirate	BAL	0.16666667	0.10322732	0.61936393	n.s.
NPV	Sputum	Induced sputum	0.00507604	0.61977665	1	n.s.
NPV	Sputum	Bronchial aspirate	-0.0058305	0.68707568	1	n.s.
NPV	Sputum	BAL	0.0070922	0.48184948	1	n.s.
NPV	Induced sputum	Bronchial aspirate	0	1	1	n.s.
NPV	Induced sputum	BAL	-0.0188537	1	1	n.s.
NPV	Bronchial aspirate	BAL	0.0019746	0.14625681	0.87754084	n.s.

562

563 **Table S5. P-values for Table 5, sensitivity of PCR to predict**
 564 **tuberculosis according to the type of specimen using a 72 72-hours**
 565 **pairing window in the same patient..**
 566

Table S5. P.values for table 5, sensitivity of PCR to predict tuberculosis according to the type of specimen using a 72-hours pairing window in the same patient..

PAIRWISE COMPARISON						
PCR	Sample1	Sample2	Diff_1m2	p.val	adj.p.val	sig.code
SENSITIVITY	Sputum	Induced sputum	0	1	1	n.s.
SENSITIVITY	Sputum	Bronchial aspirate	-0.6153846	0.00293535	0.01761212	*
SENSITIVITY	Sputum	BAL	-0.4	0.4291953	1	n.s.
SENSITIVITY	Induced sputum	Bronchial aspirate	0.14285714	1	1	n.s.
SENSITIVITY	Induced sputum	BAL	0.4	0.4291953	1	n.s.
SENSITIVITY	Bronchial aspirate	BAL	0.41025641	5.551E-05	0.00033306	***
NPV	Sputum	Induced sputum	0	1	1	n.s.
NPV	Sputum	Bronchial aspirate	-0.0473373	0.01482072	0.08892431	n.s.
NPV	Sputum	BAL	-0.0149254	0.48447295	1	n.s.
NPV	Induced sputum	Bronchial aspirate	0.03024194	1	1	n.s.
NPV	Induced sputum	BAL	0.0625	0.50109265	1	n.s.
NPV	Bronchial aspirate	BAL	0.01379293	0.00043168	0.00259007	**

567
 568

569 **Table S6. P.values for table 1, sensitivity of culture to predict**
 570 **tuberculosis according to the type of specimen using a 72-hour**
 571 **pairing window within the same patient.**

572

Table S4. P.values for table 6, sensitivity of culture to predict tuberculosis according to the type of specimen using a 72 72-hours pairing window within the same patient..

PAIRWISE CULTURE	Sample1	Sample2	Diff_1m2	p.val	adj.p.val	sig.code
SENSITIVITY	Sputum	Induced sputum	0.05714286	0.75114104	1	n.s.
SENSITIVITY	Sputum	Bronchial aspirate	-0.2903226	0.01767207	0.10603241	n.s.
SENSITIVITY	Sputum	BAL	0.10526316	0.65640773	1	n.s.
SENSITIVITY	Induced sputum	Bronchial aspirate	-0.1538462	0.64159157	1	n.s.
SENSITIVITY	Induced sputum	BAL	0.30769231	0.22653276	1	n.s.
SENSITIVITY	Bronchial aspirate	BAL	0.33333333	1.0772E-08	6.4633E-08	***
NPV	Induced sputum	0.00526184	0.77818701	1	n.s.	
NPV	Bronchial aspirate	-0.0270178	0.04176735	0.25060407	n.s.	
NPV	BAL	0.00729847	0.68809585	1	n.s.	
NPV	Bronchial aspirate	-0.0406619	0.71342494	1	n.s.	
NPV	BAL	0.08074534	0.39206894	1	n.s.	
NPV	BAL	0.00940163	3.2399E-07	1.944E-06	***	

E=sputum (spontaneous expectoration), Induced sputum=Induced sputum, Bronchial aspirate=bronchial aspirate, BAL=Bronchoalveolar lavage.

573

574

575

576

577

578 **Table S7. Performance of in-house Taqman PCR and Xpert for the**
579 **diagnostic of pulmonary tuberculosis.**

580

581

Supplementary table 2. Performance of in-house Taqman PCR and Xpert for the diagnostic of pulmonary tuberculosis.

	Accuracy	Sensitivity	Specificity	Prevalence	PPV	NPV
In-house TaqMan PCR	0.991 (0.988, 0.994) 5493/5542	0.799 (0.743, 0.848) 191/239	>0.999 (0.999, 1) 5302/5303	0.043 (0.038, 0.049) 239/5542	0.995 (0.971, 1) 191/192	0.991 (0.988, 0.993) 5302/5350
Xpert	0.975 (0.967, 0.981) 1917/1967	0.812 (0.760, 0.858) 212/261	0.999 (0.997, 1) 1705/1706	0.133 (0.118, 0.148) 261/1967	0.995 (0.974, 1) 212/213	0.972 (0.963, 0.979) 1705/1754

582

583

584 **Table S8. Kappa with 95% confidence intervals.**

585

	Microscopy	PCR	Culture
Sputum vs Induced sputum	0.73 (0.54,0.92)	0.49 (-0.11,1)	0.78 (0.66,0.9)
Sputum vs Bronchial aspirate	0.79 (0.62,0.97)	0.54 (0.26,0.81)	0.66 (0.50,0.82)
Sputum vs BAL	0.93 (0.80,1)	0.74 (0.40,1)	0.80 (0.65,0.96)
Induced sputum vs Bronchial aspirate	-0.02 (-0.04,0.01)	0.68 (0.34,1)	0.64 (0.37,0.90)
Induced sputum vs BAL	-0.02 (-0.05,0.01)	0.72 (0.36,1)	0.27 (-0.06,0.60)
Bronchial aspirate vs BAL	0.72 (0.62,0.82)	0.69 (0.56,1)	0.75 (0.67,0.83)

586

587 **Table S9. Contingency table for kappa: microscopy**

	Induced sputum	
Sputum	1	0
1	10	5
0	2	364
	Bronchial aspirate	
Sputum	1	0
1	10	1
0	4	332
	BAL	
Sputum	1	0

1	7	1
0	0	278
	Bronchial aspirate	
Induced sputum	1	0
1	0	1
0	1	54
	BAL	
Induced sputum	1	0
1	0	1
0	1	50
	BAL	
Bronchial aspirate	1	0
1	35	18
0	9	3502

588

589

590 **Table S10. Contingency table for kappa: PCR**

	Induced sputum	
Sputum	1	0
1	1	150
0	129	1927
	Bronchial aspirate	
Sputum	1	0
1	0	147
0	161	1888
	BAL	
Sputum	1	0
1	0	149
0	132	1923
	Bronchial aspirate	
Induced sputum	1	0
1	2	77
0	30	2144
	BAL	
Induced sputum	1	0
1	3	2
0	0	30
	BAL	
Bronchial aspirate	1	0
1	21	18
0	1141	1033

591

592

593 **Table S11. Contingency table for kappa: culture**

	Induced sputum	
Sputum	1	0
1	23	7
0	5	368
	Bronchial aspirate	
Sputum	1	0
1	16	3
0	12	318
	BAL	
Sputum	1	0
1	13	4
0	2	268
	Bronchial aspirate	
Induced sputum	1	0
1	7	2
0	4	43
	BAL	
Induced sputum	1	0
1	3	7
0	3	39
	BAL	
Bronchial aspirate	1	0
1	60	36
0	3	3471

594

595